Douglas I. Lin, Ph.D.
Affiliations: | 2007 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Cell Biology, Molecular Biology, OncologyGoogle:
"Douglas Lin"Parents
Sign in to add mentor| Alan Diehl | grad student | 2007 | Penn | |
| (Interplay between SCF and CDK complexes in the control of cellular proliferation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Posada JM, Yakirevich E, Kamat AM, et al. (2024) Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 100424 |
| Lin DI, Killian JK, Venstrom JM, et al. (2020) Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc |
| Huang RSP, Li X, Haberberger J, et al. (2020) Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. The Oncologist |
| Saglam O, Lin DI, Steele CB, et al. (2020) A sporadic gastric-type endocervical adenocarcinoma with endometrial involvement and bilateral ovarian metastasis, a case report. Gynecologic Oncology Reports. 32: 100572 |
| Lin DI, Hemmerich A, Edgerly C, et al. (2020) Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Gynecologic Oncology |
| Madison RW, Gupta SV, Elamin YY, et al. (2020) Urothelial Cancer Harbors EGFR and HER2 Amplifications and Exon 20 Insertions. Bju International |
| Bratslavsky G, Necchi A, Grivas P, et al. (2020) Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 727-727 |
| Yakirevich E, Perrino C, Necchi A, et al. (2020) NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study. Journal of Clinical Oncology. 38: 726-726 |
| Jacob J, Shapiro O, Necchi A, et al. (2020) Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa). Journal of Clinical Oncology. 38: 5087-5087 |
| Necchi A, Grivas P, Bratslavsky G, et al. (2020) Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC). Journal of Clinical Oncology. 38: 175-175 |